Ó Springer- Verlag 1998 Summary Type I diabetes mellitus may represent a heterogeneous disorder with a distinct pathogenesis in patients with young and adult onset of the disease. To investigate whether serological markers directed to different autoantigens have the potential to distinguish acute onset from slowly progressive Type I diabetes we analysed antibodies to tyrosine phosphatases IA-2/ICA512 (IA-2A) and IA-2b/phogrin (IA2bA), antibodies to GAD65 (GADA) and cytoplasmic islet cell antibodies (ICA) in a non-selected group of diabetic patients clinically classified as having Type I or Type II diabetes at diagnosis. Both IA-2A and IA-2bA were found to be positively associated with onset before the age of 20 years and the presentation of classical features of Type I diabetes. In Type I diabetes 56 % (112/200) of patients were positive for IA-2A and 38 % (76/200) for IA-2bA. In contrast, only 1 of 785 (0.1 %) patients with Type II diabetes had IA-2A and all of them were negative for IA-2bA (p < 0.001). Among the patients with Type II diabetes 7.6 % (n = 60) were ICA positive and 2.8 % (n = 22) had GADA suggesting the presence of slowly progressive Type I diabetes. GADA were found in 8 of 60 (13.3 %) ICA positive subjects which was lower than the percentage detected in patients with acute onset of diabetes (115/157 73.2 %) (p < 0.001). Blocking of double antibody positive sera showed that only 3 of 8 (37.5 %) patients with slowly progressive diabetes had ICA restricted to GAD or IA-2 whereas ICA were completely inhibited in 12 of 20 (60.0 %) patients with Type I diabetes. Among 193 patients with Type II diabetes available for follow-up, 35 % of ICA positives, 58 % of GADA positives and 60 % of those positive for both markers required insulin by 3 years. However, using strict criteria for the switch to insulin treatment the corresponding sensitivity of each marker was only low (9 %, 10 % and 5 %).
We show that clinical subtypes of Type I diabetes are associated with distinct humoral autoimmunity. IA-2A and GADA were associated with classical features of Type I diabetes whereas GADA and an uncharacterized ICA subspecificity indicate slowly progressive disease. [Diabetologia (1998) 
41: 891±897]
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diabetes with ketoacidosis to slowly progressing insulin deficiency where residual beta-cell function may be preserved for many years. The latter group is mainly found in adults who do not present the classical features of insulin-dependent diabetes mellitus at manifestation of the disease, thus misdirecting the classification to non insulin-dependent diabetes. Several studies suggest the presence of a slowly progressive beta-cell destruction in 3.2±14.3 % of patients who were classified as Type II diabetes at diagnosis [2±8] . Such patients are generally characterized by the presence of residual insulin secretion at diagnosis followed by a progressive decrease of insulin secretory capacity and the development of insulin dependency over the course of their disease [2±4] . Evidence for an autoimmune pathogenesis was assessed by the demonstration of cytoplasmic islet cell antibodies (ICA) or antibodies to glutamic acid decarboxylase (GADA) or both in 56±95 % of sera from patients with Type II diabetes who lost endogeneous insulin secretion 3±5 years after diagnosis [4, 5, 7±11] .
Recently, two members of the protein tyrosine phosphatase family, termed IA-2/ICA512 and IA-2b/ phogrin, have been identified as dominant target autoantigens in Type I diabetes. IA-2 antibodies (IA-2A) were detected in 50±73 % of patients with juvenile Type I diabetes [12±15] and these antibodies were found to be strongly associated with the development of Type I diabetes in non-diabetic children and adolescents [15, 16] . Comparison with cytoplasmic islet cell antibodies (ICA), the best validated to assess the risk for Type I diabetes, shows that the combination of antibodies to IA-2/ICA512 with GADA has the power to detect the majority of ICA positive individuals and 97±100 % of subjects who progressed to overt diabetes [16, 17] . These findings imply the possibility of replacing the laborious ICA test in screening programmes to identify subjects at risk for Type I diabetes. As yet it has not been known whether these results are applicable to slowly progressive Type I diabetes. One study reported on a low percentage of IA-2A (12 %) among 26 patients with slowly progressive Type I diabetes [18] . Population based data on the importance of antibodies to protein tyrosine phosphatases and their association with GADA or ICA are though not available.
In the present study, we show a heterogeneous autoimmune response in acute onset and slowly progressive Type I diabetes. We provide evidence that antibodies to protein tyrosine phosphatases are strongly associated with young age and the presence of classical features of Type I diabetes. In contrast, slowly progressive Type I diabetes is characterized by the appearance of GADA and an uncharacterized ICA subspecificity.
Materials and methods
Patients. Serum samples were obtained from 785 patients (age 64.3 ± 12.3, median 65.5, range 40.0±96.0 years) with Type II diabetes participating in a regional shared care project in Amsterdam [19] . The duration of diabetes was 0±44.9 years [mean 4.3 ± 5.0, median 1.9 years; 231 patients with recently diagnosed diabetes ( < 3 months)]. Patients with secondary diabetes were excluded. After entry in the study the need for insulin treatment was monitored for up to 3 years after diagnosis. The decision to start insulin therapy was made individually based on failure of therapy with diet and oral hypoglycaemic agents which was defined as presence of poor metabolic control (HbA 1 c > 7.0 %) despite good education and adherence to the prescribed treatment regimen. The presence of autoantibodies was used as a marker to distinguish patients with Type II diabetes from patients with an autoimmune-mediated form of diabetes.
Sera were also obtained from 200 consecutive patients with acute onset newly-diagnosed Type I diabetes (within 7 days of diagnosis) (mean age 19.4 ± 9.4, median 17.0 range 0.1±40.0 years). Diabetes was classified according to the World Health Organisation criteria [20] . Written informed consent was given by all patients participating in the study. The study was approved by the ethical committees of the centres participating in the study.
Detection of autoantibodies to protein tyrosine phosphatase IA-2, IA-2b and GAD. Autoantibodies to IA-2, IA-2b and GAD were determined using recombinant antigens in a 96-well assay format as described [17] . Plasmid cDNA coding for the intracytoplasmic domains of human IA-2 (amino acids 603±980) (a kind gift from Dr. M. Christie, London, U. K.) [12] , mouse IA-2bic (amino acids 351±-723) [21] or full length GAD65 (a kind gift from Dr. Lernmark, Seattle, Washington) [22] was in vitro transcribed and translated in the presence of [ 35 S]-methionine using a TNT rabbit reticulocyte lysate system (Promega, Madison, Wis., USA). Aliquots of radiolabelled proteins (10 000 cpm for IA-2 and IA-2û or 20 000 cpm for GAD65) were incubated with 5 ml serum in 96-well microtitre plates (Greiner, Nürtingen Germany) followed by adsorption of immunocomplexes with 20 ml Protein A Sepharose (v/ v). After extensive washing on 96-well filtration plates (Millipore, Bedford, Mass., USA) bound radioactivity was determined in a liquid scintillation counter and expressed in arbitrary units. The cut offs of the IA-2-, IA-2b-and GADA-assays were calculated as the 99th centile of normal control subjects (mean age 21.3 years, range 7±38 years, 3.4 IA-2A-U, 4.3 IA-2bA-U and 6.5 GADA-U). The inter-assay and intra-assay coefficient of variation were 9.8 % and 7.8 % (n = 10) for anti-IA-2b. The assay for the detection of GADA was evaluated in the Second GAD Antibody Proficiency Program (values of 100 % for sensitivity, specificity, validity and consistency). In the International Diabetes Combined Autoantibody Workshop our IA-2 antibody assay had a diagnostic sensitivity of 72.5 % and a specificity of 96 % for Type I diabetes.
Detection of cytoplasmic islet cell antibodies (ICA). Islet cell antibodies were detected by the indirect immunofluorescence test on unfixed cryostat sections of human pancreas from an organ donor with blood group 0 as described [23] . The detection limit of our assay was 2.5 Juvenile Diabetes Foundation units. In the 11th International Diabetes Workshop ICA Proficiency Program our laboratory achieved values of 100 % for sensitivity, specificity, validity and consistency (Laboratory identification No. 116).
Blocking studies. Blocking studies of ICA were performed in selected sera from patients classified as having Type I diabetes (20 sera GADA or IA-2A positive or both, 5 sera with ICA only) or Type II diabetes (8 sera with GADA or IA-2A or both, 5 sera with ICA only) at diagnosis. Sera were diluted to an ICA level of 10 Juvenile Diabetes Foundation units with phosphate buffered saline alone or containing a mixture of human recombinant GAD65 and IA-2ic (final concentration 2.5 mg each). After 12 h at 4°C ICA were determined by the indirect immunofluorescence test as described.
Statistical analysis. Values are given as mean ± SD unless otherwise indicated. The significance of differences between observations was tested using the the chi-square test with Yates' correction, Fisher's exact test, or Mann-Whitney test where appropriate. P values were corrected for multiple comparisons. The significance of correlations between antibody levels was tested by Spearman rank correlation. Statistical tests were performed by the Statistical Package for Social Sciences (SPSS, Chicago, Ill., USA).
Results
Prevalence of autoantibodies in patients with adult onset diabetes. The clinical and immunological features of patients are listed in Tables 1 and 2 . ICA and GADA were identified as the dominant humoral markers in patients classified as having Type II diabetes at diagnosis. Among 785 patients with Type II diabetes, 60 (7.6 %) were positive for ICA (mean ICA level 20 ± 25, range 5±160 JDF-U) and 22 had GADA (2.8 %) (mean level 41 ± 28, range 7±99 GADA-U) suggesting the presence of slowly progressive Type I diabetes. Only 1 (0.13 %) patient with Type II diabetes had IA-2A and all sera were IA-2bA negative (p < 0.001). Thus, antibodies to IA-2 and IA-2b did not significantly differ from control subjects. In contrast, 26 out of 77 (33.8 %) patients aged 21±40 years with Type I diabetes tested positive for IA-2A and 16 (20.8 %) subjects had IA-2bA (p < 0.001). Comparison of antibody frequencies in patients with Type I diabetes showed an inverse correlation between the presence of IA-2bA and IA-2A compared with age ( Table 2 ). The prevalences of both IA-2A and IA-2bA were higher in the age group 0±20 years (69.9 % and 48.8 %) as compared with subjects aged 21±30 years (41.3 % and 23.9 %) (p < 0.005) or subjects above 30 years of age (22.6 % and 16.1 %) (p < 0.001). In contrast, GADA were less frequent in patients aged 0±5 years compared with the group above 5 years of age (p < 0.05). GADA as well as ICA levels were not significantly correlated with age. In Type II diabetes the frequency of ICA, but not GADA, was increased in subjects who had a BMI under 25 kg/m 2 (12.4 %) compared with patients with BMI 25 kg/m 2 or more (6.3 %) (p < 0.01). There was no sex and age difference between antibody positive and negative patients classified as having Type I or Type II diabetes. Autoantibodies to IA-2ic (IA-2A), antibodies to IA-2b (IA-2b A), antibodies to glutamic acid decarboxylase (GADA), cytoplasmic islet cell antibodies (ICA), body mass index (BMI). Follow-up investigation. Follow-up data were available from 193 patients 3 years after entry to the study. Insulin therapy was initiated in 57 of 169 (33.7 %) antibody negative subjects and in 10 of 24 (41.7 %) antibody positive patients, of whom 6 (25.0 %) were found positive for ICA and 7 (29.2 %) for GADA (Table 4) . IA-2A were detected in only one individual who was switched to insulin therapy 2 years after diagnosis. ICA, GADA and IA-2A possess a high specificity (91.3±100 %) for the prediction of insulin requirement among an non-selected group of patients with Type II diabetes. Due to the use of strict metabolic criteria for starting with insulin therapy the corresponding sensitivities of these markers were only low (1.5±14.9 %) ( Table 4) .
Discussion
Patients with autoimmune-mediated diabetes may have a variable clinical presentation at the manifestation of the disease suggesting differences in the underlying pathogenetic processes. To define common and distinct autoimmune features in clinical subtypes of Type I diabetes we analysed autoantibody patterns in a large cohort of patients classified as having Type I or Type II diabetes at diagnosis. We show a clear difference of humoral autoimmunity in patients with acute onset or slowly progressive Type I diabetes. Among 785 unselected patients classified as having Type II diabetes only 1 had IA-2A and no serum was positive for IA-2bA whereas 56 % and 38 % of patients with Type I diabetes were positive for the respective antibodies. Subdividing the patients with Type I diabetes according to age shows that the IA-2A and IA-2bA are inversely correlated with age, ranging from 70 % and 49 % in patients below 10 years to 22.6 % and 16.1 % in diabetic patients above 30 years of age, respectively. Our observations suggest that autoimmunity to PTPs reflect a severe beta-cell destruction leading to manifestation of the disease early in life or to acute onset of diabetes and insulin dependency when present in older individuals. This is consistent with studies in prediabetic subjects where rapid progression to overt diabetes was described in subjects at risk for Type I diabetes positive for IA-2A as compared with subjects positive only for ICA or GADA [16, 24, 26] . As described for the 37 kD/40 kD antibodies and IA-2A, both the prevalence and levels of IA-2Ab were closely associated with IA-2A and both were positively correlated with ICA but not with GADA [26±28]. In agreement with these studies we found only a small fraction of sera (n = 3) containing antibodies which exclusively rec- ognized IA-2b. Competition experiments showed no difference in the reactivity of sera from young and adult onset diabetic patients in that the majority of IA-2bA could be blocked by preabsoption with IA-2 (data not shown). This supports the hypothesis that about two thirds of IA-2A positive patients develop cross-reactive autoantibodies [21, 28] . The clinical and pathogenetic importance of the heterogeneous antibody response directed to common and distinct epitopes of IA-2 and IA-2b remains as yet unclear. However, it is of interest to note that IA-2A and IA2bA double positive subjects did not differ significantly from subjects who possess either IA-2A or IA-2Ab only with respect to age, gender, and the presence of additional ICA or GADA.
In agreement with previous studies ICA and GADA were found not only to be associated with Type I diabetes but also with patients who had clinical signs of Type II diabetes at diagnosis. Both the prevalence of ICA (7.6 %) and GADA (2.8 %) were in the lower range compared with previous studies which described ICA in 3.2±14.3 % and GADA in 1.1±9.0 % among non-selected patients with Type II diabetes [2±5, 7, 8, 29] . This finding may be explained by the fact that we studied older patients (median 65.5 years) from a group with a lower incidence of Type I diabetes [30] suggesting a lower incidence of slowly progressive Type I diabetes compared with previous studies from Finland and the United Kingdom.
To evaluate further differences in the autoimmune response between acute onset and slowly progressive Type I diabetes we carried out blocking studies in ICA positive sera. Our data confirm recent findings that IA-2 and GAD are the dominant target of ICA in patients with classical features of Type I diabetes [31, 32] , but also support the hypothesis that this approach is not sufficient to identify all patients with Fig. 1A ,B. Analysis of ICA subspecificities on cryostat sections of human pancreas by preincubation of sera from patients with Type II diabetes (A) using phosphate buffered saline and (B) using a mixture of GAD65 and IA-2ic. GADA + /IA-2A + serum (1), GADA + /IA-2A-serum (2, 3) adult onset autoimmune diabetes [33] . In sharp contrast to patients with Type I diabetes, where 95 % of ICA positive subjects had GADA or IA-2A or both, we found that in patients with slowly progressive Type I diabetes 13.3 % of ICA positive subjects had GADA or IA-2A and only 3 sera had ICA restricted to GAD65 and IA-2. On the basis of our data, it cannot be decided whether those ICA recognize one or several autoantigens described in Type I diabetes, e. g. gangliosides, ICA69, carboxypeptidase H and Glima 38, or is directed to a novel autoantigen. Further studies are required to answer this question. Including the sera positive for ICA only, it is important to emphasize that the non-GAD/non-IA-2 ICA reactivity was significantly more frequent among patients with slowly progressive disease (95 %) compared with patients with acute onset Type I diabetes (less than 50 %).
We also studied the value of autoantibodies for the prediction of insulin requirement. Follow-up investigation showed that the presence of ICA, GADA or both markers had a high specificity (91, 96 and 98 %) but only a low sensitivity (9, 10 and 5 %) to indicate future need for insulin treatment. The specificities of single and combined autoantibodies that were observed are in line with previous reports but the corresponding sensitivities seem to be lower than described before [4±8] . This disagreement could, at least in part, be explained by the application of strict target HbA 1 c target values to switch treatment to insulin therapy. Furthermore, we investigated an older group of patients compared with previous studies [4±7] . In line with our results, Turner et al. [8] recently reported on a decreased sensitivity of ICA and GADA for the prediction of insulin treatment and a slower progression to insulin dependency in patients aged 45±65 years as compared with younger patients with Type II diabetes. It is important to note, however, that screening for both ICA and GADA can provide information on an autoimmune-mediated diabetes in older subject which could be useful for the selection of diabetes therapy.
In conclusion, our data provide further evidence for the concept of heterogeneity of Type I diabetes. We demonstrate that clinical subtypes of autoimmune diabetes are associated with the appearance of different autoantibodies which may reflect distinct courses of the autoimmune response correlated with rapid or slowly progressive destruction of the betacells. Since slowly progressive Type I diabetes was characterized by the presence of GADA and a still unidentified ICA, subspecificity screening for autoimmune diabetes in adults has to include both GADA and ICA. These findings could be important for accurate classification of diabetes, identification of subjects who can benefit from early insulin therapy and selection of patients for future intervention trials to delay or prevent autoimmune beta-cell destruction. 
